Literature DB >> 659573

Rubella virus hemagglutination with human and animal erythrocytes: effect of age and trypsinization.

A N Ponzi, A Pugliese, P Pertusio.   

Abstract

Sensitivity to rubella virus hemagglutination differs considerably with newborn as opposed to adult erythrocytes (RBC) in several animal species. In humans, cord RBC are 16 times more sensitive to hemagglutination, whereas hemagglutination titers with newborn RBC are 6 to 16 times higher in chickens, mice, and rabbits. This higher sensitivity is, however, short-lived, and adult RBC values are observed 7 days after birth in mice. Trypsinization has no effect on newborn RBC, but increases sensitivity of adult RBC to that of neonatal RBC and tends to diminish differences among individuals. On the other hand, trypsinization does not further enhance the very high sensitivity of pigeon, duck, and goose RBC or the low sensitivity of both newborn and adult guinea pig RBC. Human cord RBC proved suitable for use in hemagglutination-inhibition tests, since they gave titers comparable to those obtained with other types of RBC and offered some advantages: by comparison with animal RBC, they did not require adsorption to remove nonspecific agglutinins; by comparison with adult human RBC, they did not need trypsinization.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 659573      PMCID: PMC275013          DOI: 10.1128/jcm.7.5.442-447.1978

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  15 in total

1.  The effect of kaolin on immunoglobulins: an improved technique to remove the nonspecific serum inhibitor of reovirus hemagglutination.

Authors:  J J Mann; R D Rossen; J R Lehrich; J A Kasel
Journal:  J Immunol       Date:  1967-06       Impact factor: 5.422

2.  Is rubella an arbovirus?

Authors:  I H Holms; M F Warburton
Journal:  Lancet       Date:  1967-12-09       Impact factor: 79.321

3.  The use of trypsin-treated human group O erythrocytes in rubella hemagglutination-inhibition test.

Authors:  S Iwakata; L P Morrissey; A J Rhodes; N A Labzoffsky
Journal:  Arch Gesamte Virusforsch       Date:  1974

4.  Erythrocytes of Japanese quail for hemagglutination by rubella virus.

Authors:  K Soda; M Matumoto; E Tabata
Journal:  Jpn J Microbiol       Date:  1971-07

5.  Measurement of rubella antibody by hemagglutination inhibition. II. Characteristics of an improved HAI test employing a new method for the removal of non-immunoglobulin HA inhibitors from serum.

Authors:  H Liebhaber
Journal:  J Immunol       Date:  1970-04       Impact factor: 5.422

6.  Rubella-virus hemagglutination-inhibition test.

Authors:  G L Stewart; P D Parkman; H E Hopps; R D Douglas; J P Hamilton; H M Meyer
Journal:  N Engl J Med       Date:  1967-03-09       Impact factor: 91.245

7.  Rubella virus hemagglutination with a wide variety of erythrocyte species.

Authors:  N J Schmidt; J Dennis; E H Lennette
Journal:  Appl Microbiol       Date:  1971-09

8.  Modified hemagglutination-inhibition test for rubella employing human group O erythrocytes.

Authors:  N J Schmidt; J Dennis
Journal:  Appl Microbiol       Date:  1972-03

9.  Compatibility of trypsin-modified human erythrocytes in the rubella hemagglutination-inhibition test employing three serum treatment procedures.

Authors:  D B Nelson; P Quirin; S L Inhorn
Journal:  Appl Microbiol       Date:  1974-04

10.  [Differences of capacity of human erythrocytes of newborn infants and adults and trypsin-treated erythrocytes to bind rubella virus hemagglutinin].

Authors:  A Negro Ponzi; A Pugliese
Journal:  G Batteriol Virol Immunol       Date:  1977 Jan-Jun
View more
  2 in total

1.  Binding sites for rubella virus on erythrocyte membrane.

Authors:  P Mastromarino; S Rieti; L Cioè; N Orsi
Journal:  Arch Virol       Date:  1989       Impact factor: 2.574

2.  Low level rubella immunity detected by ELISA and specific lymphocyte transformation.

Authors:  E Buimovici-Klein; A J O'Beirne; S J Millian; L Z Cooper
Journal:  Arch Virol       Date:  1980       Impact factor: 2.574

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.